Stryker Corporation $SYK Shares Sold by Suncoast Equity Management

Posted by George Bondi on Jun 1st, 2026

Suncoast Equity Management lowered its holdings in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 121,793 shares of the medical technology company’s stock after selling 2,035 shares during the period. Stryker comprises about 4.3% of Suncoast Equity Management’s portfolio, making the stock its 10th biggest holding. Suncoast Equity Management’s holdings in Stryker were worth $42,807,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. New Mexico Educational Retirement Board increased its holdings in Stryker by 2.6% in the 4th quarter. New Mexico Educational Retirement Board now owns 15,909 shares of the medical technology company’s stock worth $5,592,000 after purchasing an additional 400 shares in the last quarter. Ellevest Inc. increased its stake in shares of Stryker by 1.9% in the fourth quarter. Ellevest Inc. now owns 2,201 shares of the medical technology company’s stock valued at $774,000 after buying an additional 42 shares during the period. SCS Capital Management LLC increased its stake in shares of Stryker by 1.1% in the fourth quarter. SCS Capital Management LLC now owns 6,372 shares of the medical technology company’s stock valued at $2,241,000 after buying an additional 70 shares during the period. Peapack Gladstone Financial Corp increased its stake in shares of Stryker by 1.7% in the fourth quarter. Peapack Gladstone Financial Corp now owns 89,751 shares of the medical technology company’s stock valued at $31,545,000 after buying an additional 1,512 shares during the period. Finally, Rothschild Wealth LLC increased its stake in shares of Stryker by 11.2% in the fourth quarter. Rothschild Wealth LLC now owns 1,603 shares of the medical technology company’s stock valued at $563,000 after buying an additional 161 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SYK. Needham & Company LLC decreased their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. BTIG Research cut their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Read Our Latest Analysis on Stryker

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Stryker Stock Performance

NYSE:SYK opened at $305.73 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business has a fifty day simple moving average of $321.82 and a two-hundred day simple moving average of $348.10. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a market capitalization of $117.21 billion, a P/E ratio of 35.39, a P/E/G ratio of 1.92 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the prior year, the business earned $2.84 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.